drugset / Trial / NCT03262389

Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma

NCT03262389

Phase 2 Completed 10 enrolled Michael C Roarke, MD
NaSingle-groupOpen-labelDiagnostic

Summary

Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance imaging (MRI), C-11 acetate PET CT, and C-11 acetate PET MRI) is the best test for finding sites of active myeloma disease.

Timeline

Start
2017-09-19
Primary completion
2019-11-23
Completion
2019-11-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Fludeoxyglucose Diagnostic / imaging agent 5 unknown Intravenous
Subject Fludeoxyglucose Diagnostic / imaging agent 10 unknown Intravenous
Subject Sodium Acetate Small molecule 370 mbq Intravenous

Indications